全文获取类型
收费全文 | 622篇 |
免费 | 88篇 |
国内免费 | 11篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 36篇 |
口腔科学 | 7篇 |
临床医学 | 117篇 |
内科学 | 215篇 |
皮肤病学 | 1篇 |
神经病学 | 55篇 |
特种医学 | 3篇 |
外科学 | 57篇 |
综合类 | 35篇 |
现状与发展 | 1篇 |
预防医学 | 18篇 |
眼科学 | 4篇 |
药学 | 138篇 |
中国医学 | 5篇 |
肿瘤学 | 24篇 |
出版年
2024年 | 1篇 |
2023年 | 17篇 |
2022年 | 8篇 |
2021年 | 22篇 |
2020年 | 33篇 |
2019年 | 28篇 |
2018年 | 50篇 |
2017年 | 31篇 |
2016年 | 36篇 |
2015年 | 46篇 |
2014年 | 44篇 |
2013年 | 106篇 |
2012年 | 36篇 |
2011年 | 41篇 |
2010年 | 31篇 |
2009年 | 42篇 |
2008年 | 31篇 |
2007年 | 28篇 |
2006年 | 20篇 |
2005年 | 25篇 |
2004年 | 19篇 |
2003年 | 9篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有721条查询结果,搜索用时 15 毫秒
31.
32.
Comparative analysis of the efficacy of omega‐3 fatty acids for hypertriglyceridaemia management in Korea 下载免费PDF全文
33.
Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low‐density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report 下载免费PDF全文
M. G. Zenti C. Stefanutti V. Sanga A. Altomari A. Fabris M. Dauriz E. Bonora 《Journal of clinical apheresis》2018,33(4):546-550
A 49 years old woman (weight 68 kg, BMI 27.3 kg/m2) with heterozygous familial hypercholesterolemia (HeFH) and multiple statin intolerance with muscle aches and creatine kinase elevation, presented at the Outpatient Lipid Clinic of Verona University Hospital in May 2015. Hypercholesterolemia was firstly diagnosed during adolescence, followed in adulthood by a diagnosis of Cogan's syndrome, a rheumatologic disorder characterized by corneal and inner ear inflammation. No xanthomas, corneal arcus, or vascular bruits were detectable at physical examination. Screening for macrovascular complications did not reveal relevant damages. Ongoing medical therapy included salicylic acid, methylprednisolone, methotrexate, and protonic‐pump inhibitor. In the absence of specific lipid‐lowering therapy, plasma lipid levels at first visit were: total‐cholesterol = 522 mg/dL, LDL‐cholesterol = 434 mg/dL, HDL‐cholesterol = 84 mg/dL, triglycerides = 120 mg/dL, Lp(a) = 13 mg/dL. On December 2015, evolocumab 140 mg sc every 2 weeks was initiated. After a 24‐week treatment, the LDL‐cholesterol levels decreased by an average of 21.2% to 342 ± 22 mg/dL (mean ± SD). On May 2016, LDL‐apheresis (H.E.L.P.system) was started as add‐on therapy. Compared to the average levels obtained during the evolocumab monotherapy period, the LDL‐cholesterol was reduced by 49.4%, thus reaching an inter‐apheresis level (mean ± SD) of 173 ± 37 mg/dL. This report suggests that a combination therapy with evolocumab and lipoprotein‐apheresis may have synergic effects on circulating lipid levels. Its relevance as a highly effective treatment option for hyperlipidemia in HeFH patients warrants further investigation in larger datasets. 相似文献
34.
Anjan Tibrewala Arif Jivan William J. Oetgen Neil J. Stone 《Journal of the American College of Cardiology》2018,71(7):794-799
Lipid treatment guidelines have continued to evolve as new evidence emerges. We sought to review similarities and differences of 5 lipid treatment guidelines from the American College of Cardiology/American Heart Association, Canadian Cardiovascular Society, European Society for Cardiology/European Atherosclerosis Society, U.S. Preventive Services Task Force, and U.S. Veterans Affairs/Department of Defense. All guidelines utilize rigorous evidentiary review, highlight statin therapy for primary and secondary prevention of atherosclerotic cardiovascular disease, and emphasize a clinician-patient risk discussion. However, there are differences in statin intensities, use of risk estimators, treatment of specific patient subgroups, and consideration of safety concerns. Clinicians should understand these similarities and differences in current and future guideline recommendations when considering if and how to treat their patients with statin therapy. 相似文献
35.
36.
目的:观察接受血运重建的急性冠脉综合征患者住院期间应用他汀类药物对预后的影响。方法:入选本院接受血管重建治疗并且低密度脂蛋白-胆固醇C<100 mg/dL的非ST段抬高急性冠脉综合征患者1121例,根据住院期间是否应用他汀类药物分为他汀组(668例)与非他汀组(453例)。主要不良心脑血管事件定义为死亡、新发心肌梗死、卒中和再次血管重建。结果:他汀组院内不良心血管事件发生率和随访病死率均明显降低(P<0.05,P<0.01),他汀组血管重建后累计病死率(院内及随访死亡)明显低于非他汀组(P<0.01)。经Logistic多因素回归分析,住院期间是否应用他汀类药物与累计病死率显著相关(HR,0.471;95CI,0.245~0.906;P<0.05),并且与随访病死率显著相关(HR,0.328;95CI,0.143~0.753;P<0.01)。结论:住院期间应用他汀类药物可以显著减少急性冠脉综合征患者血管重建术后的住院不良心血管事件,降低累计病死率及随访病死率。 相似文献
37.
Ozaki H Ishikawa CT Ishii T Toyoda A Murano T Miyashita Y Shirai K 《Journal of clinical pharmacy and therapeutics》2005,30(2):189-192
We report on a patient who developed acute rhabdomyolysis after taking cerivastatin. A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain. Her serum creatinine phosphokinase level was 19,190 IU/L. Serum myoglobin was over 3000 ng/mL. Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons. The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls. Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M-1, and by 2C8 to M-23. The ratio of M-23 to M-1 in her serum was much lower than that of control persons (0.64 vs. 2.08). She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction. 相似文献
38.
Bozbas H Yildirir A Mermer S Konas D Atar I Aydinalp A Ozin B Korkmaz ME Muderrisoglu H 《Advances in therapy》2007,24(3):493-504
Serum cardiac enzyme elevation after percutaneous coronary intervention (PCI), a relatively common complication, is a prognostic
determinant of long-term outcome in patients who undergo these procedures. Statins are postulated to reduce such complications.
This study investigated the short-term effects of pravastatin on serum creatine kinase myocardial isoform (CK-MB) and serum
cardiac troponin I (cTpI) levels after elective PCI. Of 93 patients studied, 72 (77.4%) were men, and 21 (22.6%) were women
(mean age, 58.9±11.0 y). Patients were randomly divided into 3 groups before they underwent elective PCI. Preoperatively,
group 1 patients (n=30) received pravastatin 10 mg/d, and group 2 patients (n=29) received pravastatin 40 mg/d. Control group
patients (n=34) received no lipid-lowering medication. Serum CK-MB and serum cTpI levels were measured preoperatively and
then again at 6, 24, and 36 h postoperatively. Demographic features of patients and characteristics of the PCI procedure,
including number of vessels/lesions and duration and number of inflations, did not differ among groups (P>.05). Mean serum CK-MB and serum cTpI levels were significantly increased after PCI in all patients (P<.001). When compared with control group patients, those given pravastatin did not experience significantly lowered postprocedural
serum CK-MB or serum cTpI levels (P>.05). Preprocedural pravastatin therapy at dosages of 10 mg/d and 40 mg/d seems inadequate for preventing serum cardiac enzyme
elevations during short-term follow-up after PCI. Additional research on this topic is recommended. 相似文献
39.
40.